Clinicopathological and molecular analysis of endometrial carcinoma associated with tamoxifen

Modern Pathology

Volumn 21, Issue 8, 2008, Pages 925-936

  Turbiner, Julia ^a   Moreno Bueno, Gema ^b   Dahiya, Sonika ^a   Sánchez Estevez, Carolina ^c   Hardisson, David ^d   Prat, Jaime ^e   Oliva, Esther ^a   Palacios, José ^f  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^c Centro Nacional de Investigaciones Oncológicas   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

catenin; Endometrial carcinoma; Estrogen; Pathogenesis; Tamoxifen

Indexed keywords

BETA CATENIN; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CANCER STAGING; CARCINOSARCOMA; CLINICAL ARTICLE; CONTROL GROUP; CONTROLLED STUDY; DNA EXTRACTION; DRUG EXPOSURE; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; ESTROGEN SYNTHESIS; GRANULOSA CELL TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; MUTATIONAL ANALYSIS; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL SIGNIFICANCE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BETA CATENIN; CARCINOMA, ENDOMETRIOID; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICROSATELLITE INSTABILITY; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS P21(RAS); PTEN PHOSPHOHYDROLASE; SURVIVAL RATE; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL;

EID: 48749086763     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2008.49     Document Type: Article

References (56)

1. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15:10-17.
2. Lax SF. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch 2004;444:213-223.
3. Matias-Guiu X, Catasus L, Bussaglia E, et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 2001;32:569-577.
4. Bilbao C, Rodriguez G, Ramirez R, et al. The relationship between microsatellite instability and PTEN gene mutations in endometrial cancer. Int J Cancer 2006;119:563-570.
5. Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000;92:924-930.
6. Fukuchi T, Sakamoto M, Tsuda H, et al. Beta-catenin mutation in carcinoma of the uterine endometrium. Cancer Res 1998;58:3526-3528.
7. Lax SF, Kendall B, Tashiro H, et al. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 2000;88:814-824.
8. Palacios J, Catasus L, Moreno-Bueno G, et al. Beta- and gamma-catenin expression in endometrial carcinoma. Relationship with clinicopathological features and microsatellite instability. Virchows Arch 2001;438:464-469.
9. Saegusa M, Hashimura M, Yoshida T, et al. Betacatenin mutations and aberrant nuclear expression during endometrial tumorigenesis. Br J Cancer 2001;84:209-217.
10. Caduff RF, Johnston CM, Frank TS. Mutations of the K-ras oncogene in carcinoma of the endometrium. Am J Pathol 1995;146:182-188.
11. Enomoto T, Inoue M, Perantoni AO, et al. K-ras activation in neoplasms of the human female reproductive tract. Cancer Res 1990;50:6139-6145.
12. Sasaki H, Nishii H, Takahashi H, et al. Mutation of the K-ras protooncogene in human endometrial hyperplasia and carcinoma. Cancer Res 1993;53:1906-1910.
13. Black D, Soslow RA, Levine DA, et al. Clinicopathologic significance of defective DNA mismatch repair in endometrial carcinoma. J Clin Oncol 2006;24:1745-1753.
14. Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis 2000;21:427-433.
15. Key TJ, Pike MC. The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer 1988;57:205-212.
16. Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 2006;24:4783-4791.
17. Guzeloglu-Kayisli O, Kayisli UA, Al-Rejjal R, et al. Regulation of PTEN (phosphatase and tensin homolog deleted on chromosome 10) expression by estradiol and progesterone in human endometrium. J Clin Endocrinol Metab 2003;88:5017-5026.
18. Guzeloglu Kayisli O, Kayisli UA, Luleci G, et al. In vivo and in vitro regulation of Akt activation in human endometrial cells is estrogen dependent. Biol Reprod 2004;71:714-721.
19. Mutter GL, Lin MC, Fitzgerald JT, et al. Changes in endometrial PTEN expression throughout the human menstrual cycle. J Clin Endocrinol Metab 2000;85:2334-2338.
20. Goldstein SR. The effect of SERMs on the endometrium. Ann N Y Acad Sci 2001;949:237-242.
21. ACOG committee opinion. No. 336: Tamoxifen and uterine cancer. Obstet Gynecol 2006;107:1475-1478.
22. Deligdisch L, Kalir T, Cohen CJ, et al. Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. Gynecol Oncol 2000;78:181-186.
23. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388.
24. Mourits MJ, Ten Hoor KA, van der Zee AG, et al. The effects of tamoxifen on proliferation and steroid receptor expression in postmenopausal endometrium. J Clin Pathol 2002;55:514-519.
25. Schwartz LB, Krey L, Demopoulos R, et al. Alterations in steroid hormone receptors in the tamoxifen-treated endometrium. Am J Obstet Gynecol 1997;176:129-137.
26. Wu H, Chen Y, Liang J, et al. Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis. Nature 2005;438:981-987.
27. Shang Y. Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis. Nature Rev 2006;6:360-368.
28. Shang Y. Hormones and cancer. Cell Research 2007;17:277-279.
29. Bartsch H, Phillips DH, Nair J, et al. Lack of evidence for tamoxifen- and toremifene-DNA adducts in lymphocytes of treated patients. Carcinogenesis 2000;21:845-847.
30. Carmichael PL, Sardar S, Crooks N, et al. Lack of evidence from HPLC 32P-post-labelling for tamoxifen-DNA adducts in the human endometrium. Carcinogenesis 1999;20:339-342.
31. Beland FA, McDaniel LP, Marques MM. Comparison of the DNA adducts formed by tamoxifen and 4-hydroxytamoxifen in vivo. Carcinogenesis 1999;20:471-477.
32. Schild LJ, Divi RL, Beland FA, et al. Formation of tamoxifen-DNA adducts in multiple organs of adult female cynomolgus monkeys dosed with tamoxifen for 30 days. Cancer Res 2003;63:5999-6003.
33. Shibutani S, Suzuki N, Laxmi YR, et al. Identification of tamoxifen-DNA adducts in monkeys treated with tamoxifen. Cancer Res 2003;63:4402-4406.
34. Tavasolli F, Devilee P. WHO Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. IARC Press: Lyon, 2003, pp 221-228.
35. Moreno-Bueno G, Hardisson D, Sanchez C, et al. Abnormalities of the APC/beta-catenin pathway in endometrial cancer. Oncogene 2002;21:7981-7990.
36. Dahia PL, Marsh DJ, Zheng Z, et al. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res 1997;57:4710-4713.
37. Shibutani S, Ravindernath A, Suzuki N, et al. Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen. Carcinogenesis 2000;21:1461-1467.
38. Terashima I, Suzuki N, Shibutani S. Mutagenic potential of alpha-(N2-deoxyguanosinyl) tamoxifen lesions, the major DNA adducts detected in endometrial tissues of patients treated with tamoxifen. Cancer Res 1999;59:2091-2095.
39. Hou X, Tan Y, Li M, et al. Canonical Wnt signaling is critical to estrogen-mediated uterine growth. Mol Endocrin 2004;18:3035-3049.
40. Katoh M. Expression and regulation of WNT1 in human cancer: up-regulation of WNT1 by beta-estradiol in MCF-7 cells. Int J Oncol 2003;22:209-212.
41. Easwaran V, Pishvaian M, Salimuddin, et al. Cross-regulation of beta-catenin-LEF/TCF and retinoid signaling pathways. Curr Biol 1999;9:1415-1418.
42. Truica CI, Byers S, Gelmann EP. Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res 2000;60:4709-4713.
43. Gielen SC, Kuhne LC, Ewing PC, et al. Tamoxifen treatment for breast cancer enforces a distinct gene-expression profile on the human endometrium: an exploratory study. Endocr Relat Cancer 2005;12:1037-1049.
44. Brachtel EF, Sanchez-Estevez C, Moreno-Bueno G, et al. Distinct molecular alterations in complex endometrial hyperplasia (CEH) with and without immature squamous metaplasia (squamous morules). Am J Surg Path 2005;29:1322-1329.
45. Esteller M, Garcia A, Martinez-Palones JM, et al. Endometrial carcinoma in tamoxifen-treated breast cancer patient: clinicopathological, immunohistochemical, and genetic analysis. Int J Gynecol Pathol 1999;18:387-391.
46. Hachisuga T, Miyakawa T, Tsujioka H, et al. K-ras mutation in tamoxifen-related endometrial polyps. Cancer 2003;98:1890-1897.
47. Wallen M, Tomas E, Visakorpi T, et al. Endometrial K-ras mutations in postmenopausal breast cancer patients treated with adjuvant tamoxifen or toremifene. Cancer Chemother Pharmacol 2005;55:343-346.
48. Kato K, Horiuchi S, Takahashi A, et al. Contribution of estrogen receptor alpha to oncogenic K-Ras-mediated NIH3T3 cell transformation and its implication for escape from senescence by modulating the p53 pathway. J Biol Chem 2002;277:11217-11224.
49. Kato K, Ueoka Y, Kato K, et al. Contribution of enhanced transcriptional activation by ER to [12Val] K-Ras mediated NIH3T3 cell transformation. Oncogene 1997;15:3037-3046.
50. Prasad M, Wang H, Douglas W, et al. Molecular genetic characterization of tamoxifen-associated endometrial cancer. Gynecol Oncol 2005;96:25-31.
51. Holtz D, Ramondetta LM, Burke TW, et al. PTEN expression in tamoxifen-associated endometrial cancers. Anticancer Res 2002;22:2945-2948.
52. Mutter GL, Ince TA, Baak JP, et al. Molecular identification of latent precancers in histologically normal endometrium. Cancer Res 2001;61:4311-4314.
53. Vilgelm A, Lian Z, Wang H, et al. Akt-mediated phosphorylation and activation of estrogen receptor alpha is required for endometrial neoplastic transformation in Pten+/- mice. Cancer Res 2006;66:3375-3380.
54. Notarnicola M, Gristina R, Messa C, et al. Oestrogen receptors and microsatellite instability in colorectal carcinoma patients. Cancer Lett 2001;168:65-70.
55. Caldes T, Perez-Segura P, Tosar A, et al. Microsatellite instability correlates with negative expression of estrogen and progesterone receptors in sporadic breast cancer. Teratog Carcinog Mutagen 2000;20:283-291.
56. Shen KL, Yang LS, Hsieh HF, et al. Microsatellite alterations on human chromosome 11 in in situ and invasive breast cancer: a microdissection microsatellite analysis and correlation with p53, ER (estrogen receptor), and PR (progesterone receptor) protein immunoreactivity. J Surg Oncol 2000;74:100-107.